Both, classical NAD-like and non-NAD-like PARP-1 inhibitors reduced viability and clonogenic potential of ccRCC cell lines and suppressed growth of ccRCC xenograft tumors. This evidence concerns the gene PARP1 and nonpapillary renal cell carcinoma.